Quattrode; Octrode; Penta; Lamitrode; Tripole; TriCentrus Lead Extensions
ABBOTT MEDICAL · Decision date Sep 18, 2026
What did the FDA approve?
The FDA decision dated 2026-09-18 is an approval of supplement P010032/S251 from Abbott Medical, filed under the 30-day notice review track with the reason given as process change affecting manufacturer, sterilizer, packager or supplier. The source statement describes two manufacturing items at Abbott's Arecibo, Puerto Rico facility: optimized process parameter ranges for injection molding equipment used to make Bionate® 55D injection-molded portions at the stimulation and terminal ends of the listed leads and lead extensions, and qualification of a second injection molding machine identical in make, model and configuration to the existing Nissei STX10 machine.
The identifier links this to the original PMA P010032, which the source lists for the product code LGW spinal-cord stimulator category; the action covers the listed leads and extensions rather than the whole system. The statement reports the applicant's stated purposes only. It does not present independent data on safety, performance or clinical outcomes, and none are assessed here. Details such as changed parameter values, qualification test results or the original device scope beyond these fields are absent from the supplied text.
FDA approval order statement
1) optimization of the process parameter ranges of the injection molding equipment used in the manufacturing of the Bionate 55D injection-molded portions at the stimulation and terminal ends of the Quattrode; Octrode; Penta; Lamitrode; Tripole; and TriCentrus Leads and Lead Extensions at the Abbott manufacturing facility in Arecibo, Puerto Rico; and 2) qualification of a second injection molding machine of identical make, model, and configuration to the existing Nissei STX10 Machine at the Abbott manufacturing facility in Arecibo, Puerto Rico.
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Sep 18, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010032/S251
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- LGW
- Decision code
- APPR
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Abbott Medical
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010032. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010032 · Original PMA
GENESIS AND EON FAMILY NEUROSTIMULATION (IPG) SYSTEMS
P010032/S251 received
Application receipt date recorded by FDA.
P010032/S261 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
P010032/S251 · FDA decision
135 Review Track For 30-Day Notice
P010032/S260 · Related supplement
Proclaim family of SCS IPG
P010032/S265 · Related supplement
Eterna Spinal Cord Stimulation (SCS) Implantable Pulse Generator
P010032/S262 · Related supplement
Spinal Cord Stimulation (SCS) External Pulse Generator (EPG)
P010032/S264 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
P010032/S266 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG)
Timeline entries are records held by MedtechLedger for P010032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Nov 21, 2001 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 11, 2026 | FDA | |
Proclaim family of SCS IPGP010032/S260 | ABBOTT MEDICAL | PMA supplement | Sep 23, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Oct 27, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S052 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 16, 2026 | FDA |
Saluda Medical Evoke SCS SystemP190002/S051 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 15, 2026 | FDA |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 6901 Preston Rd., Plano, TX, 75024
Sources and methodology
- Original FDA record: P010032/S251
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






